LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Начало・Списък с акции・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Затворен

СекторЗдравеопазване

64.67 -3.03

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

63.67

Максимум

67.39

Ключови измерители
By Trading Economics
Приходи	-7.5M -190M
Продажби	33M 154M
Марж на печалбата	-123.403
Служители	834
EBITDA	-6.9M -180M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+58.35% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	361M 13B
Предишно отваряне	67.7
Предишно затваряне	64.67

Настроения в новините

By Acuity

50%

153 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.71 / 36.9 Подкрепа & съпротива

Bridgebio Pharma Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Gold Falls on Renewed Inflation Concerns -- Market Talk

10.05.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10.05.2026 г., 23:38 ч. UTC

Пазарно говорене

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10.05.2026 г., 23:14 ч. UTC

Пазарно говорене

Australia's Political Map Continues to Be Redrawn -- Market Talk

10.05.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium: Expects Deal to Close in 1Q FY27

10.05.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10.05.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10.05.2026 г., 10:21 ч. UTC

Печалби

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9.05.2026 г., 06:05 ч. UTC

Печалби

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8.05.2026 г., 23:55 ч. UTC

Печалби

Review & Preview: Still Going Strong -- Barrons.com

8.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 20:49 ч. UTC

Печалби

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8.05.2026 г., 20:25 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Net $115M

8.05.2026 г., 19:20 ч. UTC

Пазарно говорене

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8.05.2026 г., 19:18 ч. UTC

Печалби

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8.05.2026 г., 19:16 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:08 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:05 ч. UTC

Печалби

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8.05.2026 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8.05.2026 г., 18:51 ч. UTC

Печалби

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8.05.2026 г., 18:49 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 18:41 ч. UTC

Печалби

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8.05.2026 г., 17:14 ч. UTC

Печалби

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8.05.2026 г., 17:04 ч. UTC

Пазарно говорене

Zcash Caps Off Parabolic Week -- Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Bridgebio Pharma Inc Прогноза

Ценова цел

By TipRanks

58.35% нагоре

12-месечна прогноза

Среден 106.71 USD 58.35%

Висок 157 USD

Нисък 81 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Bridgebio Pharma Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

18 ratings

Купи

Задържане

Продай

Според 18 анализатори, дали борсови рейтинги на Bridgebio Pharma Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.71 / 36.9Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

153 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.